Anticoagulant effects of low-molecular-weight heparins in healthy cats

Journal of Veterinary Internal Medicine

Volumn 21, Issue 3, 2007, Pages 378-387

  Alwood, Amy J ^a,d   Downend, Amanda B ^a   Brooks, Marjory B ^b   Slensky, Kimberly A ^a   Fox, Julia A ^a   Simpson, Stephen A ^a   Waddell, Lori S ^a   Baumgardner, James E ^a   Otto, Cynthia M ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c Oscillogy   (United States)

^d Allegheny Veterinary Emergency Trauma and Specialty   (United States)

Author keywords

Anti Xa; Dalteparin; Enoxaparin; Feline; Thromboelastography

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; LOW MOLECULAR WEIGHT HEPARIN;

ABSORPTION; ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CAT; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFECT; METABOLISM; METHODOLOGY; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZATION; THROMBOELASTOGRAPHY;

ABSORPTION; ANIMALS; ANTICOAGULANTS; ANTITHROMBIN III; CATS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES; PROTHROMBIN TIME; RANDOM ALLOCATION; THROMBELASTOGRAPHY;

ANIMALIA; FELIDAE;

EID: 34249291055     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2007)21[378:AEOLHI]2.0.CO;2     Document Type: Article

References (36)

1. Hirsh J, Anand S, Halperin J, Fuster V. Guide to anticoagulant therapy: Heparin, a statement for healthcare professionals from the American Heart Association. Arterioscler Thromb Vase Biol 2001;21:e9-e33.
2. Hirsh J, Raschke R. Heparin and low molecular weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl):188S-203S.
3. Weitz JI. Drug therapy: Low molecular weight heparins [Review]. New Engl J Med 1997;337:688-698.
4. Levine M, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:49-56.
5. Kakkar V, Howes J, Sharma V, Kadziola Z. A comparative double-blind, randomized trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism: The Bemiparin Assessment group. Thromb Haemost 2000;83:523-529.
6. Farooq V, Hegarty J, Chanddrasekar T, et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kid Dis 2004;43:531-537.
7. Chandler W. The thromboelastography and the thromboelastograph technique. Sem Thromb Hemost 1995;21(suppl 4):1-6.
8. Klein SM, Slaughter TF, Vail PT, et al. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: A comparison with anti-Xa concentrations. Anesth Analg 2000;91:1091-1095.
9. Zmuda K, Neofotistos D, Tsao C. Effects of unfractionated heparin, low molecular weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J Clin Path 2000;113:725-731.
10. Otto CM, Rieser TM, Brooks MB, Russell MW. Evidence of hypercoagulability in dogs with parvoviral enteritis. J Am Vet Med Assoc 2000;217:1500-1504.
11. Donahue SM, Otto CM. Thromboelastography: A tool for measuring hypercoagulability, hypocoagulability, and fibrinolysis. J Vet Emerg Crit Care 2005;15:9-16.
12. Grebe S, Jacobs C, Kietzmann M, Mischke R. Pharmacokinetics of the low molecular weight heparin Fragmin D in dogs [in German]. Berl Munch Tierarztl Wochenschr 2000;113:103-107.
13. Mischke R, Grebe S. The correlation between plasma antifactor Xa activity and haemostatic tests in healthy dogs, after the administration of a low molecular weight heparin. Res Vet Sci 2000;69:241-247.
14. Mischke R, Grebe S, Jacobs C, Kietzmann M. Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs. Am J Vet Res 2001;62:595-598.
15. Mischke R, Fehr M, Nolle I. Efficacy of low molecular weight heparin in a canine model of thromboplastin-induced acute disseminated intravascular coagulation. Res Vet Sci 2005;79:69-76.
16. Smith CE, Rozanski EA, Freeman LM, et al. Use of low molecular weight heparin in cats: 57 cases (1999-2003). J Am Vet Med Assoc 2004;225:1237-1241.
17. Schwarzwald C, Feige K, Wunderlie-Allenspach H, Braun U. Comparison of pharmacokinetic variables for two low molecular weight heparins after subcutaneous administration of a single dose to horses. Am J Vet Res 2002;63:868-873.
18. Feige K, Schwarzwald C, Bombeli T. Comparison of unfractionated and low molecular weight heparin for prophylaxis of coagulopathies in 52 horses with colic: A randomised double-blind clinical trial. Equine Vet J 2003;35:506-513.
19. Smith S, Tobias A. Feline arterial thromboembolism: An update. Vet Clin Small Animal 2004;34:1245-1271.
20. Kittleson MD. Small Animal Cardiovascular Medicine. St. Louis, MO: Mosby; 1998:
21. Fareed J, Fu K, Yang L, Hoppensteadt D. Pharmacokinetics of low molecular weight heparins in animal models. Sem Thromb Hemost 1999;25(suppl 3):51-55.
22. Brooks MB. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma. Vet Clin Path 2004;33:208-214.
23. Greene C, Meriwether E. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats. Am J Vet Res 1982;43:1473-1477.
24. Ritschel WA. Handbook of Basic Pharmacokinetics: Including Clinical Applications, 3rd ed. Hamilton, IL: Drug Intelligence Publications; 1986.
25. Winter ME. Basic Clinical Pharmacokinetics, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.
26. Montalescot G, Collet J, Tanguy M, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004;110:392-398.
27. Collignon F, Frydman A, Caplain H, et al. Comparison of pharmacokinetic profiles of three low molecular mass heparins: Dalteparin, enoxaparin, and nardoparin - administered subcutaneously in healthy volunteers. Thromb Haemost 1995;73:630-640.
28. Boneu B. Low molecular weight heparin therapy: Is monitoring needed? Thromb Haemost 1994;72:330-334.
29. Fareed J, Jeske W, Hoppensteadt D, et al. Low molecular weight heparins: Pharmacologic profile and product differentiation. Amer J Cardiol 1998;82:3L-10L.
30. Fraser GL, McKenna JP. Monitoring low molecular weight heparins with anti-Xa activity: House of cards or firm foundation? Hosp Pharm 2003;38:202-211.
31. Hoppensteadt D, Walenga J, Fareed J, et al. Heparin, low molecular weight heparins, and heparin pentasaccharide: Basic and clinical differentiation. Hematol Onco Clin North Am 2003;17:313-341.
32. Laposta M, Green D, Van Cott E, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. Arch Pathol Lab Med 1998;122:799-807.
33. Yee JYV, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. Eur J Clin Pharmacol 2000;56:293-297.
34. Al Dieri R, Wagenvoord R, VanDedem G, et al. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif: The C-domain. J Thromb Haemost 2003;1:907-914.
35. Levi M. All heparins are equal but some are more equal. J Thromb Haemost 2003;1:884-885.
36. Melissari E, Parker C, Wilson N, et al. Use of low molecular weight heparin in pregnancy. Thromb Haemostasis 1992;68:652-656.